Logo
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ελληνικά 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Σύνδεση
Προβολή τεκμηρίου 
  •   Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Προβολή τεκμηρίου
  •   Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Προβολή τεκμηρίου
JavaScript is disabled for your browser. Some features of this site may not work without it.
Ιδρυματικό Αποθετήριο Πανεπιστημίου Θεσσαλίας
Όλο το DSpace
  • Κοινότητες & Συλλογές
  • Ανά ημερομηνία δημοσίευσης
  • Συγγραφείς
  • Τίτλοι
  • Λέξεις κλειδιά

Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19

Thumbnail
Συγγραφέας
Dalekos G.N., Stefos A., Georgiadou S., Lygoura V., Michail A., Ntaios G., Samakidou A., Giannoulis G., Gabeta S., Vlychou M., Petinaki E., Leventogiannis K., Giamarellos-Bourboulis E.J., Gatselis N.K.
Ημερομηνία
2021
Γλώσσα
en
DOI
10.1016/j.ejim.2021.03.026
Λέξη-κλειδί
alanine aminotransferase
anakinra
antibiotic agent
C reactive protein
D dimer
dexamethasone
enoxaparin
ferritin
granulocyte colony stimulating factor
hydrocortisone
immunoglobulin
lactate dehydrogenase
methylprednisolone
remdesivir
tocilizumab
interleukin 1 receptor blocking agent
adult
adult respiratory distress syndrome
alanine aminotransferase level
algorithm
anasarca
Article
bacteremia
bacterial pneumonia
bloodstream infection
breathing rate
Candida
catheter infection
chronic obstructive lung disease
combination drug therapy
comorbidity
computer assisted tomography
controlled study
coronary artery disease
coronavirus disease 2019
COVID-19 testing
diabetes mellitus
disease duration
disease severity
drug half life
drug megadose
drug pulse therapy
drug withdrawal
female
ferritin blood level
follow up
fraction of inspired oxygen
heart failure
hematoma
hospital admission
hospital infection
hospital patient
hospitalization
human
hypertension
immunotherapy
injection site reaction
intubation
Kolmogorov Smirnov test
lactate dehydrogenase blood level
leukocyte count
lower respiratory tract infection
lung embolism
lung infiltrate
lymphocyte count
lymphocytopenia
major clinical study
male
mesenteric vein thrombosis
mortality rate
nasopharyngeal swab
neutropenia
neutrophil count
obesity
observational study
osteoporosis
oxygen saturation
oxygen tension
oxygen therapy
pathophysiology
peripheral edema
phase 3 clinical trial (topic)
platelet count
pneumonia
prospective study
pulse oximetry
respiratory failure
risk factor
secondary infection
single drug dose
Stenotrophomonas maltophilia
thorax radiography
thrombocytopenia
treatment contraindication
treatment duration
treatment outcome
aged
middle aged
respiratory distress syndrome
respiratory failure
Aged
COVID-19
Female
Humans
Interleukin 1 Receptor Antagonist Protein
Male
Middle Aged
Respiratory Distress Syndrome
Respiratory Insufficiency
SARS-CoV-2
Treatment Outcome
Elsevier B.V.
Εμφάνιση Μεταδεδομένων
Επιτομή
Aims Infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may lead to the development of severe respiratory failure. In hospitalized-patients, prompt interruption of the virus-driven inflammatory process by using combination treatments seems theoretically of outmost importance. Our aim was to investigate the hypothesis of multifaceted management of these patients. Methods A treatment algorithm based on ferritin was applied in 311 patients (67.2% males; median age 63-years; moderate disease, n=101; severe, n=210). Patients with ferritin <500ng/ml received anakinra 2-4mg/kg/day ± corticosteroids (Arm A, n=142) while those with ≥500ng/ml received anakinra 5-8mg/kg/day with corticosteroids and γ-globulins (Arm B, n=169). In case of no improvement a single dose of tocilizumab (8mg/kg; maximum 800mg) was administered with the potential of additional second and/or third pulses. Treatment endpoints were the rate of the development of respiratory failure necessitating intubation and the SARS-CoV-2-related mortality. The proposed algorithm was also validated in matched hospitalized-patients treated with standard-of-care during the same period. Results In overall, intubation and mortality rates were 5.8% and 5.1% (0% in moderate; 8.6% and 7.6% in severe). Low baseline pO2/FiO2 and older age were independent risk factors. Comparators had significantly higher intubation (HR=7.4; 95%CI: 4.1-13.4; p<0.001) and death rates (HR=4.5, 95%CI: 2.1-9.4, p<0.001). Significant adverse events were rare, including severe secondary infections in only 7/311 (2.3%). Conclusions Early administration of personalized combinations of immunomodulatory agents may be life-saving in hospitalized-patients with COVID-19. An immediate intervention (the sooner the better) could be helpful to avoid development of full-blown acute respiratory distress syndrome and improve survival. © 2021
URI
http://hdl.handle.net/11615/73017
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19674]

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients 

    Laskari K., Tektonidou P.M.G., Katsiari P.C., Athanassiou P., Dimopoulou D., Gerodimos C., Salamaliki C., Papagoras P.C., Settas P.L., Vassilopoulos P.D., Voulgari P.P.V., Zakalka M., Georgiadis A., Gkoni G., Daoussis P.D., Dimitroulas P.T., Iliou C., Kallitsakis I., Grika E.P., Mavragani P.C., Pikazis P.D., Raftakis J., Sarikoudis T., Kougkas N., Soukera D., Theodorou E., Tsatsani P., Tsiakou E., Vlachoyiannopoulos P.P., Vosvotekas G., Sfikakis P.P.P. (2021)
    Objective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methods
  • Thumbnail

    Obstructive sleep disordered breathing in 2- to 18-year-old children: Diagnosis and management 

    Kaditis A.G., Alvarez M.L.A., Boudewyns A., Alexopoulos E.I., Ersu R., Joosten K., Larramona H., Miano S., Narang I., Trang H., Tsaoussoglou M., Vandenbussche N., Villa M.P., Waardenburg D.V., Weber S., Verhulst S. (2016)
    This document summarises the conclusions of a European Respiratory Society Task Force on the diagnosis and management of obstructive sleep disordered breathing (SDB) in childhood and refers to children aged 2-18 years. ...
  • Thumbnail

    Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial 

    Woodhouse L.J., Scutt P., Hamdy S., Smithard D.G., Cohen D.L., Roffe C., Bereczki D., Berge E., Bladin C.F., Caso V., Christensen H.K., Collins R., Czlonkowska A., de Silva A., Etribi A., Laska A.-C., Ntaios G., Ozturk S., Phillips S.J., Prasad K., Szatmari S., Sprigg N., Bath P.M. (2018)
    Post-stroke dysphagia is common, associated with poor outcome and often requires non-oral feeding/fluids. The relationship between route of feeding and outcome, as well as treatment with glyceryl trinitrate (GTN), was ...
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013
Με τη συγχρηματοδότηση της Ελλάδας και της Ευρωπαϊκής Ένωσης
htmlmap 

 

Πλοήγηση

Όλο το DSpaceΚοινότητες & ΣυλλογέςΑνά ημερομηνία δημοσίευσηςΣυγγραφείςΤίτλοιΛέξεις κλειδιάΑυτή η συλλογήΑνά ημερομηνία δημοσίευσηςΣυγγραφείςΤίτλοιΛέξεις κλειδιά

Ο λογαριασμός μου

ΣύνδεσηΕγγραφή (MyDSpace)
Πληροφορίες-Επικοινωνία
ΑπόθεσηΣχετικά μεΒοήθειαΕπικοινωνήστε μαζί μας
Επιλογή ΓλώσσαςΌλο το DSpace
EnglishΕλληνικά
Η δικτυακή πύλη της Ευρωπαϊκής Ένωσης
Ψηφιακή Ελλάδα
ΕΣΠΑ 2007-2013
Με τη συγχρηματοδότηση της Ελλάδας και της Ευρωπαϊκής Ένωσης
htmlmap